CMMB
Chemomab Therapeutics Ltd (CMMB)
Healthcare • NASDAQ • $1.77+1.72%
- Symbol
- CMMB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.77
- Daily Change
- +1.72%
- Market Cap
- $12.74M
- Trailing P/E
- N/A
- Forward P/E
- -59.00
- 52W High
- $5.88
- 52W Low
- $1.35
- Analyst Target
- $15.00
- Dividend Yield
- N/A
- Beta
- 0.51
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Company websiteResearch CMMB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.